Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9766680 | 1.00 | SIGMAR1 (0.55) | SIGMAR1MAOACHRM2EPHX2HDAC3 | |
| Hydrochloric Acid SCHEMBL28119181 | 0.98 | SIGMAR1 (0.53) | SIGMAR1MAOACHRM2EPHX2HDAC3 | |
| SCHEMBL2936967 | 0.98 | SIGMAR1 (0.56) | SIGMAR1MAOACHRM2EPHX2HDAC3 | |
| SCHEMBL11129280 | 0.92 | HDAC3 (0.51) | SIGMAR1MAOACHRM2EPHX2HDAC3 | |
| SCHEMBL30454697 | 0.89 | SIGMAR1 (0.51) | SIGMAR1MAOACHRM2EPHX2HDAC3 | |
| SCHEMBL2893366 | 0.84 | MEN1 (0.50) | SIGMAR1MAOACHRM2HDAC3HDAC8 | |
| SCHEMBL2889761 | 0.82 | MAOA (0.80) | SIGMAR1MAOACHRM2HRH4HRH3 | |
| SCHEMBL5950191 | 0.82 | MAOA (0.80) | SIGMAR1MAOACHRM2HRH4HRH3 | |
| SCHEMBL253468 | 0.82 | MAOA (0.80) | SIGMAR1MAOACHRM2HRH4HRH3 | |
| SCHEMBL2748121 | 0.82 | MAOA (0.80) | SIGMAR1MAOACHRM2HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202910-B2 | Compositions and methods for treatment of infectious disease | SEQUELLA, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20090192173-A1 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | SEQUELLA, INC. | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192173-A1 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | RIF1, TERT, ELL | SIGMAR1 3044/4885MAOA 1983/4885CHRM2 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.